Warsaw, Poland on July 19, 2010. Dr. Ferrick will describe how investigators are employing the Seahorse XF Analyzer to measure cellular bioenergetics in Alzheimer’s and Parkinson’s, obesity, diabetes cancer and cardiovascular drug discovery and research.
“Today’s XF technology is enabling researchers to elucidate metabolic mechanisms that drive degenerative diseases and aging,” observed Dr. Ferrick. “Almost every degenerative disease tested seems to have some mitochondrial dysfunction. Measuring mitochondrial function is essential to obesity, diabetes, cardiovascular and neurodegeneration research, but the tools have been effectively unchanged for fifty years. The Seahorse XF Analyzer has changed that.”
Held every other year, EBEC is a leading scientific conference that brings together scientists from around the world to present their achievements and to discuss problems in molecular and cellular bioenergetics.
“This is an ideal forum for learning about technological advances in bioenergetics,” added David Nicholls, PhD, FRSE, Professor at the Buck Institute for Aging and also an EBEC speaker. “I immediately recognized the power of the XF Analyzer. It is the only instrument to simultaneously measure the two major energy pathways of the cell in a microplate. Not only has it transformed the productivity of my lab it has changed the way we design our experiments. My post-docs cannot imagine research without a Seahorse.”
About Seahorse Bioscience
Seahorse XF instruments are the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, visit http://www.seahorsebio.com.
Media Contact: Cynthia Egan | |
Phone: 978.671.1610 | |
SOURCE Seahorse Bioscience, Inc.
